钱海研究员，博士生导师，现任中国药科大学发展规划与学科建设处处长&多靶标天然药物全国重点实验室新药研究中心主任。
兼任美国化学会Jounal of Medicinal Chemistry杂志副主编（associate editor）和中国药学会麻醉药物专业委员会委员
主要从事创新药物分子发现和结构优化研究。针对糖尿病、肿瘤、疼痛等重大临床问题，以多肽、核酸和小分子药物为研究对象，基于药物靶点及药物分子的结构特点进行合理设计，并从受体、细胞及整体动物等不同层面深入探讨和确证相关化合物的药效机制，为创新药物开发奠定坚实基础。
在创新药物研究方面已取得一系列重要成果。合成得到了超过1500个全新化合物，发现具有良好成药性、值得进一步开发的活性化合物超过20个，4个候选化合物正处于临床前研究阶段；一项静脉麻醉药物已转让国内知名药企。
发表SCI收录学术期刊论文120多篇。申请中国专利29项，国际专利4项，授权中国专利10余项。曾获中国药学会施维雅青年药物化学奖，2013年增补为江苏省“333高层次人才培养工程”培养对象。
近期发表主要论著：
1. Yang Zhang#, Yiqing Fan#, Shuyu Liu#, Yonghui Guan, Jiale Wan, Qiang Ren, Jialing Wang, Li Zhong, Zhipeng Hu, Wei Shi*, and Hai Qian*. Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide−Drug Conjugates for Targeted Cancer Therapy. Journal of Medicinal Chemistry, 2024, 67(13) :10967−10985.
2. Xianjing Zhou#, Ping Zhang#, Yuyan Yang, Wei Shi, Lei Liu, Zhencheng Lai, Xing Zhang, Peichen Pan, Lan Li, Juan Du, Hai Qian*, and Sunliang Cui*. Highly Potent and Intestine Specific P-Glycoprotein Inhibitor to Enable Oral Delivery of Taxol. Angewandte Chemie-international Edition, 2024: e202412649.
3. Qianqian Qiu#, Fanglian Chi#, Daoguang Zhou#, Zhancheng Xie, Yunxiao Liu, Hanyu Wu, Ziyu Yin,Wei Shi*, and Hai Qian*. Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers. Journal of Medicinal Chemistry, 2023, 66(8) :5753−5773.
4. Wei Shi#, Zhenzhen Tong#, Shuang Chen, Qianqian Qiu, Jiaqi Zhou, Hai Qian*. Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8+ T cells and enhancing their function. Immunology, 2023, 169(4) :454–466.
5. Jiaqi Zhou#, Xiaojian Bian#, Zigui Kan, Zilong Cai, Yuxuan Jiang, Zike Wang, Yuanyuan Li, Wei Shi* and Hai Qian*. In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide−Camptothecin Conjugates for HER2-Positive Breast Cancer. Journal of Medicinal Chemistry, 2022, 65(22): 15123−15139.
6. Wei Shi, Qianqian Qiu, Ziying Feng, Zhenzhen Tong,Weiwei Guo, Feng Zou, Na Yue, Wenlong Huang, Hai Qian*. Design, synthesis and immunological evaluation of self- assembled antigenic peptides from dual-antigen targets: a broad-spectrum candidate for an effective anti-breast cancer therapy. Journal for ImmunoTherapy of Cancer, 2021, 9 :e002523.
7. Qianqian Qiu#, Feng Zou#, Huilan Li#, Wei Shi, Daoguang Zhou, Ping Zhang, Teng Li, Ziyu Yin, Zilong Cai, Yuxuan Jiang, Wenlong Huang, and Hai Qian*. Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P‐gp- and BCRP-Mediated Multidrug Resistance. Journal of Medicinal Chemistry, 2021, 64(9) :6179−6197.
8. Yao Ma#, Dawei Yin#, Jingjia Ye#, Xiduan Wei, Yameng Pei, Xueyuan Li, Guangxu Si, Xuan-Yu Chen, Zhe-Sheng Chen, Yi Dong, Feng Zou, Wei Shi, Qianqian Qiu, Hai Qian*, Gang Liu*. Discovery of Potent Inhibitors against P‐Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2‐(4-(Pyridin-2-yl)phenoxy)pyridine Analogue. Journal of Medicinal Chemistry, 2020, 63(10): 5458−5476.
9. Qiu Qianqian#, Liu Baomin#, Cui Jian, Li Zheng, Deng Xin, Qiang Hao, Li Jieming, Liao Chen, Zhang Bo, Shi Wei, Pan Miaobo, Huang Wenlong*, Qian Hai*. Design, Synthesis, and Pharmacological Characterization of N (4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P Glycoprotein-Mediated Multidrug Resistance. Journal of Medicinal Chemistry, 2017, 60(8):3289-3302.
10. Qiu Qianqian, Shi Wei, Li Zheng, Zhang Bo, Pan Miaobo, Cui Jian, Dai Yuxuan, Huang Wenlong*, Qian Hai*. Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. Journal of Medicinal Chemistry, 2017, 60(7) :2930-2943.
11. Han Jing #, Sun Lidan #, Huang Xun #, Li Zheng, Zhang Chenyu, Qian Hai *, Huang Wenlong*. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability. British Journal of Pharmacology, 2014, 171(23) :5252-5264.
12. Han Jing#, Sun Lidan#, Chu Yingying, Li Zheng, Huang Dandan, Zhu Xiaoyun, Qian Hai*, Huang Wenlong*. Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates. Journal of Medicinal Chemistry, 2013, 56(24) :9955-9968.
联系地址：江苏省南京市江宁大学城中国药科大学行政楼7楼（211198）
电 话：025-86185286
E-mail: qianhai24@cpu.edu.cn or qianhai24@163.com